Predictive Biomarkers for Pneumonitis After Chemoradiotherapy and Immunotherapy in Patients With Non-small Cell Lung Cancer

Summary

This study looks at the side effects of chemotherapy and radiation (chemoradiation) followed by immunotherapy in patients with non-small cell lung cancer, with a particular focus on lung inflammation (pneumonitis). By collecting blood, stool and saliva samples, and data from lung function tests, researchers may be able to create a database of information about treatment and side effects in patients with non-small cell lung cancer who are receiving chemoradiation followed by immunotherapy. The information gained from this study may also help researchers find signs of problems with lung function earlier rather than later, since lung function is checked more often than routine care. This may improve how quickly these issues can be treated, and future patients may benefit from what is learned.

Eligibility

Inclusion Criteria:

* Newly-diagnosed NSCLC patients who will be undergoing concurrent chemotherapy and radiotherapy (XRT) followed by immune checkpoint inhibitors (CPI) therapy with durvalumab, as per the PACIFIC trial
* Willing to undergo all treatment and evaluation at MD Anderson Cancer Center (MDACC)
* Has access to a smartphone with the ability to transmit data via wireless connection or through their personal cellular plan
* Able and willing to perform home spirometry (HS) weekly without absolute contraindications to performing spirometry

Conditions3

Interventions1

Locations1 site

Find trials near these locations

Related trials

• A Single-cell Approach to Identify Biomarkers of Efficacy and Toxicity for ICI in NSCLC — Universitaire Ziekenhuizen KU Leuven
• Albumin-bound Paclitaxel-based Second-line Treatment Regimens for Locally Advanced or Metastatic G/GEJ Adenocarcinoma — Fudan University
• Biomarkers in Immunotherapy of Melanoma — Institute of Oncology Ljubljana
• Chemotherapy With or Without Immune Checkpoint Inhibitors for Lung Cancer — Hunan Province Tumor Hospital
• Glycoprotein in Immunotherapy Response and Efficacy Prediction of Lung Cancer — Shanghai Chest Hospital
• IC Plus Low-dose Radiation Plus Cadonilimab in LANPC — Sun Yat-sen University
• ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI — Peking Union Medical College Hospital
• Immune Checkpoint Inhibitors + Chemotherapy Versus Chemotherapy in the Neoadjuvant Treatment of Locally Advanced Colorectal Cancer — Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Browse More Trials